Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H (SFOSF)
OTHER OTC:SFOSF
SFOSF Stock Chart & Stats
$2.78
-$0.10(-5.62%)
At close: 4:00 PM EST
$2.78
-$0.10(-5.62%)
Day’s Range― - ―
52-Week Range$1.94 - $3.50
Previous CloseN/A
Volume200.00
Average Volume (3M)46.00
Market Cap
$7.96B
Enterprise Value$88.21B
Total Cash (Recent Filing)$15.29B
Total Debt (Recent Filing)$31.86B
Price to Earnings (P/E)16.7
Beta<0.01
Next Earnings
Sep 01, 2026EPS Estimate
0.06Next Dividend Ex-DateN/A
Dividend Yield1.76%
Share Statistics
EPS (TTM)1.30
Shares Outstanding551,940,500
10 Day Avg. Volume20
30 Day Avg. Volume46
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market Cap11.08
Enterprise Value/Revenue2.11
Enterprise Value/Gross Profit4.18
Enterprise Value/Ebitda18.74
Forecast
1Y Price Target
$3.98Price Target Upside43.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.19
Revenue Forecast (FY)$5.62B
Bulls Say, Bears Say
Bulls Say
Revenue ReboundA pronounced TTM revenue rebound (+158.4%) signals recovery in core demand and successful commercialization or portfolio normalization. Sustained higher revenue improves operating leverage, funds R&D and distribution scale, and provides a firmer base for multi-quarter profit stability.
Healthy Gross MarginsA ~49% gross margin indicates durable product-level pricing power or efficient manufacturing; combined with an 8.1% net margin, it shows the company can convert sales into profits. These margins support reinvestment and resilience against cyclicality if product mix and cost controls remain stable.
Diversified Healthcare ModelOperating across manufacturing, distribution and medical services spreads revenue drivers and reduces single-segment exposure. Scale in distribution and integrated services supports cross-selling, procurement advantages, and steadier cash generation versus firms relying on a single product or channel.
Bears Say
Weak Cash ConversionFCF at ~24% of net income and a history of volatility mean reported profits are not translating reliably into cash. That constrains the company’s ability to self-fund capex, R&D, dividends or debt reduction, and raises vulnerability to working-capital swings or higher investment needs.
Moderate LeverageA debt-to-equity ratio around 0.75 reflects meaningful leverage that limits financial flexibility. In a higher-rate or slower-cash environment, interest and refinancing obligations could pressure margins or restrict strategic actions like acquisitions or accelerated R&D spending.
Only Average Returns; Margin PressureROE near 7% and declining EBITDA margins versus prior years indicate only average capital returns and emerging cost or mix pressures. Persistently moderate returns can limit reinvestment ROI and shareholder value creation, especially if competitive dynamics or price controls intensify.
Shanghai Fosun Pharmaceutical (Group) Co News
SFOSF FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was $1.94 and its highest was $3.50 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is $7.96B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Sep 01, 2026 which is in 86 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported $0.049 earnings per share for the quarter, beating the consensus estimate of $0.048 by <$0.001.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of $0.045 which represents an annual dividend yield of 1.76%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.06.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of $0.049 in its last earnings report, beating expectations of $0.048. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in SFOSF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.98 (43.14% Upside)
$3.98 (43.14% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
7.19%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. develops, manufactures, and sells pharmaceutical products in Mainland China and internationally. It operates in five segments: Pharmaceutical Manufacturing, Medical Devices and Medical Diagnosis, Healthcare Service, Pharmaceutical Distribution and Retail, Other Business segments. The company offers pharmaceutical products in the areas of tumor, immune modulation, metabolism, alimentary and central nervous system. It also provides medical devices and diagnostic products. In addition, the company offers health care and hospital management services. Further, it engages in retail and wholesale distribution of medicines. Shanghai Fosun Pharmaceutical (Group) Co., Ltd. was founded in 1994 and is based in Shanghai, China.
SFOSF Stock 12 Month Forecast
Average Price Target
$3.98
▲(43.14% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―
Ownership Overview
―
Insiders
3.46% Mutual Funds
― Other Institutional Investors
94.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---